Grifols, S.A.
GRFS
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $6.5B
$7.83
▲ +1.29%
P/E
10.01
Mkt Cap
$6.5B
52-Wk Range
$6.96–$10.23
52-Week Range
$6.96 - $10.23
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 20.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
+1.3% over 3m
Quality
Stable
Strong fundamentals
Dividend
Modest
0.83% yield
Smart-money signal
Who's buying GRFS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
JUL 28, 2026
Reported EPS of $0.25 vs $0.27 consensus (-7.0% surprise). Revenue of $2.1B vs $2.2B expected (-1.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.0%
Revenue trend · last 8Q
—
—
—
—
+4%
-1%
-4%
-1%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.1B
$2.3B
$2.1B
$2.2B
$2.2B
$2.3B
$2.0B
$2.2B
Margins · last 8Q
Profit
8.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GRFS stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.